Guru Subramanian Guru Murthy, MD MS
DISCLAIMER
The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
SUMMARY
This ongoing phase 1b/2 study evaluated investigational sonrotoclax plus azacitidine in patients with treatment-naïve (TN) acute myeloid leukemia (AML) considered unfit for intensive chemotherapy. This analysis reported the safety and efficacy results of the study across European LeukemiaNet (ELN) 2024 risk groups. As of May 1, 2026, 95 patients with TN unfit AML were treated (74% de novo; 26% secondary). At a median follow-up of 11.5 (range, 0.3-59.0) months, 88% of patients discontinued treatment, and 12% remained on therapy. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in nearly all patients (99%); most commonly, neutropenia (46%), febrile neutropenia (43%), decreased neutrophil count (42%), anemia (39%), thrombocytopenia (38%), decreased platelet count (34%), and pneumonia (20%) were reported. Grade 5 TEAEs occurred in 12% of patients, most frequently due to infections and infestations (6%). Tumor lysis syndrome was observed in 4 patients (2 clinical) and resolved without sequelae. Overall, 55% of patients achieved complete remission (CR) and 68% achieved CR or CR with incomplete hematologic recovery (CR/CRi); 87% of CR patients achieved CR by the end of cycle 4, with median times to CR and CR/CRi of 1.9 and 1.3 months, respectively. Across ELN 2024 genetic risk groups, CR rates ranged from 40% to 67%, while CR/CRi rates ranged from 60% to 82%. Median duration of response was 21.2 months (95% CI, 7.5-not estimable [NE]; favorable), 6.9 months (95% CI, 2.4-8.7; intermediate), and 12.8 months (95% CI, 6.3-NE; adverse). Measurable residual disease negativity (<10⁻³) among CR patients was 46%-50% across risk groups by the end of cycle 7.
ClinicalTrials.gov ID: NCT04771130
Haitao Wang, PhD
Alvaro Alencar, MD
Nakhle S. Saba, MD
Are you a returning user?
LOGINFor new users, please select your country/region
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed